While increased thirst is not listed as a direct side effect in FDA prescribing information, some patients report experiencing this symptom during treatment
In their trials, the 25 mg Wegovy pill produced an average weight loss of 13.6% over 64 weeks, while the 7.2 mg Wegovy injection produced 20.7% over 72 weeks
Medicaid varies by state
In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with WEGOVY injection compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%) [see Adverse Reactions (6.1)]
At week 72, the percentage change in weight was -15.0% with 5 mg of tirzepatide, -19.5% with 10 mg, and -20.9% with 15 mg, compared to -3.1% with the placebo
Intra-group analyses were performed using either the paired t test or the Wilcoxon matched-pair signed rank test according to the parametric or non-parametric distribution of variables